3.05
-0.135(-4.25%)
Currency In USD
| Previous Close | 3.18 |
| Open | 3.2 |
| Day High | 3.2 |
| Day Low | 2.98 |
| 52-Week High | 5.26 |
| 52-Week Low | 2.76 |
| Volume | 342,884 |
| Average Volume | 586,613 |
| Market Cap | 321.19M |
| PE | -7.81 |
| EPS | -0.39 |
| Moving Average 50 Days | 4.19 |
| Moving Average 200 Days | 4.11 |
| Change | -0.14 |
If you invested $1000 in MaxCyte, Inc. (MXCT) since IPO date, it would be worth $179.12 as of March 13, 2025 at a share price of $3.045. Whereas If you bought $1000 worth of MaxCyte, Inc. (MXCT) shares 3 years ago, it would be worth $575.61 as of March 13, 2025 at a share price of $3.045.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
GlobeNewswire Inc.
Feb 12, 2025 7:00 AM GMT
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseasesROCKVILLE, Md
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Feb 07, 2025 7:00 AM GMT
ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
GlobeNewswire Inc.
Jan 30, 2025 7:00 AM GMT
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeu